HIV

HIV test can distinguish the prevalence of antibodies corresponding with a new or established infection.

Rilipivirine exposure was up to 40% lower among pregnant patients with HIV.

Top news of the week from Specialty Pharmacy Times.

The CDC finds people between the ages of 15 to 44 are significantly more likely to have never been tested for HIV.

Testing the social networks of patients newly-diagnosed with HIV could reveal other cases of the infection.

Combination antiretroviral therapy found to elevate the risk of heart attack and adverse effects on the cardiovascular system.

Tenofovir disoproxil fumarate tablets treat HIV-1 infection in adults and pediatric patients ages 12 years and older.

Top articles of the week from The American Journal of Pharmacy Benefits.

A look at last week's top stories in the world of pharmacy.

A look at last week's top stories in the world of pharmacy.

HIV reservoirs are resistant to CD8+ T-cells, which eliminate infected cells.

Top news of the week from Specialty Pharmacy Times.

Patients may be less likely to undergo a blood test to diagnose HIV.

Novel HIV test combines the convenience of the saliva test with the reliability of the blood test.

Analytical treatment interruption may not cause long-term damage to patients with HIV.

A look at last week's top stories in the world of pharmacy.

A look at last week's top stories in the world of pharmacy.

Top news of the week from Specialty Pharmacy Times.

The researchers concluded that this information has implications for all privatized, market-based prescription drug plans.

Once-weekly pill has the potential to prevent 20% of new HIV infections.

An HIV protein may interact with brain cells to increase neurodegeneration.

Novel HIV treatment protected immune cells against HIV for nearly a month.

More than one-third of HIV-positive patients are not vaccinated against hepatitis B virus.

Certain hormonal forms of birth control could place women at a higher risk of contracting HIV.

ART was associated with lower rates of high-risk human papillomavirus and invasive cervical cancer among women with HIV.

Although substantial progress has been made in the advancement of HIV treatment and prevention, adherence remains a barrier for individuals taking medication on a frequent basis.

Many patients with HIV are unaware of their status, increasing risk for transmission of infection and leaving individuals susceptible to adverse events. For this reason, health advocates recommend that all individuals receive an HIV test.

Implementing a one-time screening for HIV at age 25 may be a cost-effective way to identify new infections.

Infectious disease and HIV specialists may be more willing to prescribe HIV preexposure prophylaxis than primary care providers.

Oral preexposure prophylaxis (PrEP) has the potential to prevent HIV transmission and ultimately to help eradicate this devastating viral infection.